Press Releases

Date Headline
7/15/2022
Zymeworks Announces Plan to Become a Delaware Corporation
 Summary
Enhances alignment with US shareholder base and other peer biotechnology companies Positions company for growth while helping to reduce complexity and certain administrative costs The Company’s name, brand, and ticker symbol to remain unchanged VANCOUVER, British Columbia & SEATTLE --(BUSINESS  Continue Reading
6/27/2022
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
 Summary
Dr. Moore will lead Zymeworks’ Early Research & Development Group   responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jun.  Continue Reading
6/10/2022
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
 Summary
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc.  Continue Reading
5/27/2022
Zymeworks Announces Participation in Upcoming Investor Conference
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--May 27, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: Jefferies  Continue Reading
5/26/2022
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
 Summary
Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer Zanidatamab in combination with chemotherapy and tislelizumab shows 75.8% cORR and 100% disease control rate (DCR) in  Continue Reading
5/20/2022
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
 Summary
Opportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders Shareholders are right to question the motive behind an activist proposal that was concurrently released to the media and sent to the company without any previous  Continue Reading
5/4/2022
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
 Summary
Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma ( GEA ) Presented topoisomerase 1 inhibitor (TOPO1i)  Continue Reading
5/2/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--May 2, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: H.C.  Continue Reading
4/28/2022
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 28, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE  Continue Reading
4/28/2022
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 28, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical  Continue Reading
Displaying 11 - 20 of 34
Copyright 2022 , Zymeworks Inc.